237 related articles for article (PubMed ID: 34712359)
1. Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway.
Gad S; Le Teuff G; Nguyen B; Verkarre V; Duchatelle V; Molinie V; Posseme K; Grandon B; Da Costa M; Job B; Meurice G; Droin N; Mejean A; Couve S; Renaud F; Gardie B; Teh BT; Richard S; Ferlicot S
Oncol Lett; 2021 Dec; 22(6):835. PubMed ID: 34712359
[TBL] [Abstract][Full Text] [Related]
2. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
4. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
5. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
[TBL] [Abstract][Full Text] [Related]
6. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
7. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
8. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
10. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma.
Murakami A; Wang L; Kalhorn S; Schraml P; Rathmell WK; Tan AC; Nemenoff R; Stenmark K; Jiang BH; Reyland ME; Heasley L; Hu CJ
Oncogenesis; 2017 Jan; 6(1):e287. PubMed ID: 28092369
[TBL] [Abstract][Full Text] [Related]
11. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
Vlachostergios PJ; Papathanassiou M; Anagnostou M; Thodou E; Tamposis I; Mitrakas L; Zachos I; Koukoulis GK; Samara M; Tzortzis V
F1000Res; 2023; 12():918. PubMed ID: 38933491
[TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
13. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
Mehdi A; Riazalhosseini Y
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
[TBL] [Abstract][Full Text] [Related]
14. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and Predictive Value of
Carril-Ajuria L; Santos M; Roldán-Romero JM; Rodriguez-Antona C; de Velasco G
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861590
[TBL] [Abstract][Full Text] [Related]
17. Natural history of Von Hippel-Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study.
Wang J; Zhang L; Qiu J; Li Z; Wu Y; Zhang C; Yao L; Gong K; Li X; Zhou L
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2631-2641. PubMed ID: 34709473
[TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
20. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
